Pleiad Devices Selects OmniComm Systems' TrialMaster

Article

Company News Release

Fort Lauderdale, FL-August 25, 2009

OmniComm Systems' EDC tool, TrialMaster, has been selected by Pleiad, Inc., a Cambridge, Massachusetts based Contract Research Organization (CRO) with European operations in the UK, to provide eClinical services to its customers. Pleiad’s investment will provide it with the products and services to manage two upcoming studies investigating the use of ophthalmic medical devices. This partnership is expected to generate more than $1 million to OmniComm over the next few years. Pleiad has worked with the TrialMaster EDC tool since April 2008 under OmniComm’s CRO Preferred Program, and is now transitioning to a Technology Transfer model in order to provide greater value to its customers engaged in these important clinical trials.

“We are pleased to once again be collaborating with Pleiad, as the exposure generated from working closely on a continual basis with such a specialized, internationally renowned CRO will undoubtedly raise our profile within the international clinical community,” commented Stephen Johnson, OmniComm’s COO. “We expect that as we continue to work with well respected, high profile organizations such as Pleiad, we will continue to attract companies of an equally high caliber to our dramatically enhanced service offering. We feel that we can offer organizations engaged in clinical research a significant advantage over their peers with our highly specialized portfolio of eClinical solutions designed to greatly simplify the clinical process.”

“TrialMaster has been an essential option for us to provide to our customers. Much is made about the importance of subject compliance in clinical research, but we find that study coordinator 'compliance' is also very critical. The TrialMaster EDC system is very intuitive, so the study coordinators with whom we work have little problem in getting their work completed within the allocated time,” stated Stephen Brandao, Pleiad’s Vice President of Business Development. “We find that OmniComm is an attentive partner, very much in tune with the needs of our business. Our team anticipates collaborating with them on future opportunities.”

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.